Head to Head Survey: Navidea Biopharmaceuticals (NYSE:NAVB) and Alpha Teknova (NASDAQ:TKNO)
Head to Head Survey: Navidea Biopharmaceuticals (NYSE:NAVB) and Alpha Teknova (NASDAQ:TKNO)
Alpha Teknova (NASDAQ:TKNO – Get Rating) and Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.
Alpha Teknova（纳斯达克股票代码：TKNO — 获取评级）和 Navidea Biopharmaceuticals（纽约证券交易所代码：NAVB — 获取评级）都是小型医疗公司，但哪家企业更好？我们将根据两家公司的机构所有权实力、分析师建议、盈利能力、估值、收益、风险和股息对比这两家公司。
Insider and Institutional Ownership
内部所有权和机构所有权
24.6% of Alpha Teknova shares are held by institutional investors. Comparatively, 5.6% of Navidea Biopharmaceuticals shares are held by institutional investors. 15.2% of Alpha Teknova shares are held by company insiders. Comparatively, 32.4% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Alpha Teknova的24.6％的股票由机构投资者持有。相比之下，Navidea Biopharmaceuticals的股票中有5.6％由机构投资者持有。15.2％的Alpha Teknova股票由公司内部人士持有。相比之下，Navidea Biopharmaceuticals的股份中有32.4％由公司内部人士持有。强大的机构所有权表明对冲基金、大型基金经理和捐赠机构认为，从长远来看，公司的表现将优于市场。
Risk & Volatility
风险与波动性
Alpha Teknova has a beta of -0.8, meaning that its share price is 180% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Alpha Teknova的beta值为-0.8，这意味着其股价的波动性比标准普尔500指数低180％。相比之下，Navidea Biopharmaceuticals的beta值为1.38，这意味着其股价的波动性比标准普尔500指数高38％。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Teknova | -43.93% | -13.25% | -10.60% |
| Navidea Biopharmaceuticals | -2,209.23% | -517.32% | -222.49% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 阿尔法·特克诺娃 | -43.93% | -13.25% | -10.60% |
| Navidea 生物制药 | -2,209.23% | -517.32% | -222.49% |
Analyst Ratings
分析师评级
This is a summary of current ratings and recommmendations for Alpha Teknova and Navidea Biopharmaceuticals, as reported by MarketBeat.com.
据Marketbeat.com报道，这是Alpha Teknova和Navidea Biopharmaceuticals目前的评级和建议摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Teknova | 0 | 0 | 2 | 0 | 3.00 |
| Navidea Biopharmaceuticals | 0 | 0 | 0 | 0 | N/A |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 阿尔法·特克诺娃 | 0 | 0 | 2 | 0 | 3.00 |
| Navidea 生物制药 | 0 | 0 | 0 | 0 | 不适用 |
Alpha Teknova currently has a consensus price target of $22.50, indicating a potential upside of 416.06%. Given Alpha Teknova's higher probable upside, equities analysts clearly believe Alpha Teknova is more favorable than Navidea Biopharmaceuticals.
Alpha Teknova目前的共识目标价为22.50美元，表明潜在的上涨空间为416.06％。鉴于Alpha Teknova可能有更高的上行空间，股票分析师显然认为Alpha Teknova比Navidea Biopharmaceuticals更有利。
Valuation and Earnings
估值和收益
This table compares Alpha Teknova and Navidea Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
该表比较了Alpha Teknova和Navidea Biopharmaceuticals的收入、每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Teknova | $36.89 million | 3.32 | -$9.80 million | ($0.67) | -6.51 |
| Navidea Biopharmaceuticals | $530,000.00 | 16.84 | -$11.73 million | ($0.40) | -0.73 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 阿尔法·特克诺娃 | 3689 万美元 | 3.32 | -980 万美元 | (0.67 美元) | -6.51 |
| Navidea 生物制药 | 530,000.00 美元 | 16.84 | -1173 万美元 | (0.40 美元) | -0.73 |
Alpha Teknova has higher revenue and earnings than Navidea Biopharmaceuticals. Alpha Teknova is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Alpha Teknova的收入和收益高于Navidea Biopharmaceuticals。Alpha Teknova的交易市盈率低于Navidea Biopharmaceuticals，这表明它目前是这两只股票中更实惠的一只。
Summary
摘要
Alpha Teknova beats Navidea Biopharmaceuticals on 8 of the 13 factors compared between the two stocks.
Alpha Teknova在两只股票比较的13个因素中有8个击败了纳威德亚生物制药公司。
About Alpha Teknova
关于 Alpha Tekno
(Get Rating)
（获取评分）
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Alpha Teknova, Inc. 为美国和国际上的生命科学市场提供关键试剂。其试剂可以发现、开发和生产生物制药产品，例如药物疗法、新型疫苗和分子诊断。该公司提供用于细胞生长和克隆的预浇培养基板；用于细胞扩张的液体细胞培养基和补充剂；以及用于样本处理、重悬和纯化的分子生物学试剂。它为生命科学市场提供服务，包括制药和生物技术公司、合同开发和制造组织、体外诊断特许经营以及学术和政府研究机构。该公司成立于1996年，总部位于加利福尼亚州霍利斯特。
About Navidea Biopharmaceuticals
关于 Navidea Bioparmaceuticals
(Get Rating)
（获取评分）
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Navidea Biopharmaceuticals, Inc. 是一家生物制药公司，专注于精准免疫诊断药物和免疫疗法的开发和商业化。它通过两个部门运营，即诊断物质和治疗开发计划。该公司开发了 Manocept 平台，用于靶向活化巨噬细胞上表达的 CD206 甘露糖受体，用于一系列诊断方式，包括单光子发射计算机断层扫描、正电子发射断层扫描 (PET)、伽玛扫描、术中和/或光学荧光检测，以及靶向巨噬细胞以及免疫和炎症相关疾病的治疗化合物的输送。它开发了 NAV3-31，已完成评估成像可重复性、可重复性和稳定性的 IIb 期临床试验，以及用于治疗中度至重度类风湿关节炎 (RA) 患者的抗肿瘤坏死因子 α 疗法的 tc99m tilmanocept 成像能力；NAV3-35 正在进行 RA 成像 IIb 期临床试验；NAV3-33，正处于 RA 成像 IIb 期临床试验；以及 NAV3-32，这是针对涉及 RA 的关节的 2b 期试验。该公司还在开发用于心血管、卡波西肉瘤、结核病和其他免疫治疗应用的tc99m tilmanocept。该公司前身为Neoprobe Corporation，并于 2012 年 1 月更名为 Navidea Biopharmaceuticals, Inc.Navidea Biopharmaceuticals, Inc. 成立于1983年，总部位于俄亥俄州都柏林。
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Alpha Teknova Daily 的新闻和 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Alpha Teknova及相关公司的最新新闻和分析师评级的简明每日摘要。